Replies to post #6465 on Halozyme Therapeutics Inc (HALO)

[maumar]

You should take a look at the convertible NVTA just issued. Perhaps I am missing some important details but it appears that Halo was able to get better terms. It's not an identical situation but similar. NVTA raised $1.2B. Their market cap now is about $8B, strong revenue growth and good prospects, though not profitable yet. It doesn't sound like they'll use the funds for stock buybacks and they announced an acquisition the same day of the issue, all of which I would've preferred to see with Halo but perhaps we've been too negative on this.

I am more concerned about the lack of new deals, especially large deals since the BMY agreement (9/2017), the uncertainty about when we will get new Enhanze products, etc.